Financial Performance: Q2 FY27

  • Revenue from Operations stood at ₹1,120 Million, compared to ₹1,018 Million in Q2 FY26, representing growth.
  • Total Income was ₹1,149 Million, a 9.9% increase from ₹1,045 Million in Q2 FY26.
  • EBIDTA was ₹408 Million (EBIDTA Margin of 35.5%), compared to ₹369 Million (35.3% margin) in Q2 FY26, a 10.5% increase.
  • Profit Before Tax (PBT) was ₹275 Million (PBT Margin of 24.0%), a 4.8% increase from ₹263 Million (25.1% margin) in the year-ago quarter.
  • Profit After Tax (PAT) was ₹206 Million (PAT Margin of 17.9%), a 3.5% increase from ₹199 Million (19.1% margin) in Q2 FY26.
  • Basic Earnings Per Share (EPS) was ₹4.6, up from ₹4.5 in Q2 FY26.

Financial Performance: H1 FY27

  • Revenue from Operations for the first half was ₹2,211 Million, compared to ₹1,994 Million in H1 FY26.
  • Total Income was ₹2,278 Million, an 11.8% increase from ₹2,038 Million in H1 FY26.
  • EBIDTA was ₹819 Million (EBIDTA Margin of 36.0%), a 13.2% increase from ₹723 Million (35.5% margin) in H1 FY26.
  • Profit Before Tax (PBT) was ₹559 Million (PBT Margin of 24.5%), an 8.4% increase from ₹515 Million (25.3% margin) in the prior year period.
  • Profit After Tax (PAT) was ₹417 Million (PAT Margin of 18.3%), a 7.3% increase from ₹388 Million (19.0% margin) in H1 FY26.
  • Basic Earnings Per Share (EPS) for H1 FY27 was ₹9.3, up from ₹8.7 in H1 FY26.

Balance Sheet & Capital Structure Highlights (as of September 30, 2026)

  • Market Capitalization was reported as ₹2,694.95 Crore.
  • Promoter Holding is 35.64%, with a Free Float of 64.36%.
  • Free-float market cap is ₹1,734.42 Crore.
  • Total Debt is ₹144.34 Million.
  • Cash & Cash Equivalents (including other bank balances) stand at ₹701.12 Million.
  • Total Shares Outstanding are 4,46,99,859.
  • The 3-month average daily trading volume (ADTV) was 4,05,173.04 shares, valued at ₹24.74 Crore.

Company Overview & Business Segments

Vimta Labs Ltd, established in 1984, is a contract research and testing organization (CRTO). Its offerings are segmented into:

1. Drug Discovery & Development Services: Includes pharma analytical, clinical research, and preclinical research services. Accreditations include USFDA, WHO, EMA, CDSCO, OECD-GLP.

2. Biologics - Contract R&D Services: Focuses on process and product development for the biotech & biopharma industry, including cell line development and analytical development.

3. Food, Agri & Environmental Testing: Services for food, beverages, animal feed, and environmental monitoring. Has 8 labs across India. Accreditations include FSSAI, ISO 17025, BIS, APEDA. The Hyderabad lab is a National Reference Lab for Water & Beverages, and the Mumbai lab is a National Food Laboratory operated for FSSAI.

4. Electricals & Electronics Testing & Certification: Services include EMI/EMC, radio frequency, and environmental testing. Accreditations include NABL ISO 17025, TEC, BIS. Operates from 2 locations in Hyderabad.

Management Team

  • Dr. S P Vasireddi: Executive Chairman and founder, with over 45 years of experience.
  • Harita Vasireddi: Managing Director, with close to 3 decades of experience. Holds a B.Pharm and an MBA.
  • Sreenivas Neerukonda: Executive Director, responsible for strategic planning. Holds a B.Pharm and an MBA.
  • Harriman Vungal: Executive Director - Operations, with extensive lab operations management experience.
  • Siva Kambhampati: Chief Financial Officer, a Chartered Accountant.

Forward-Looking Statements

The presentation contains standard forward-looking statements subject to risks and uncertainties including general economic conditions, ability to implement strategy, technological changes, currency fluctuations, interest rates, regulatory changes, and competition.